300233.SZ
金城医药
SZSE · Basic Materials · C 制造业 · CN
CNY 13.07
−5.08%Year over year
Reported trailing growth
- Revenue
- -12.6%
- EBITDA
- —
- EBIT
- -44.9%
- EPS
- -54.9%
- Free cash flow
- +125.9%
- Operating cash flow
- +68.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -7.9%
- EBITDA
- -12.6%
- EBIT
- -38.0%
- Net income
- -45.5%
- EPS
- -44.7%
- Free cash flow
- -17.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026